Safety and immune response study of YKYY025 RSV vaccine
Part of Infections, Lungs & breathing clinical trials.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 49 years old (for Part 1) or 50 or older (for Part 2).
- You cannot have received an RSV vaccine or been in an RSV vaccine study before.
- You should not have had a confirmed RSV infection in the last 6 months.
- You must not be taking long-term immune-suppressing medicines (like high-dose steroids for 2 weeks or more).
- You may not have a history of heart conditions like myocarditis or pericarditis.
- Women who can get pregnant must use birth control for at least 2 weeks before the shot and until 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.